- About us
- Join Putnam
Explore our latest insights and perspectives in these life science resources, news articles, and events.
We set out to understand the likelihood of regulatory approval of oncology-based single-arm trials by the European Medical Agency (EMA).
As provisions of the Inflation Reduction Act (IRA) of 2022 begin to take effect, Putnam continues to analyze the implications…
Putnam is pleased to announce the addition of Stephen McGarry to the team. Steve started with Putnam in June 2023 as a...
Putnam aimed to conduct an aggregate DCEA of two NSCLC treatments recommended by NICE, and identify key drivers of the analysis.
Supporting and empowering patients are objectives stated by nearly every life science company. Yet efforts to support patient engagement often...
Putnam PHMR’s client needed a detailed description of multiple myeloma treatment patterns and resource utilization in Japanese patients...
The dialogue at the Medical Affairs Strategic Summit East conference highlighted the enthusiasm within Medical Affairs to leverage artificial
An emerging biotech sought Putnam’s guidance to design and execute the global commercialization of their asset for a rare oncology indication.
A global, top-10 pharma client sought Putnam’s guidance on developing a lean launch strategy for a novel cell therapy in oncology.
A rapidly shifting healthcare landscape and a wave of cost-containment initiatives destined to put further pressure on the pricing of pharmaceuticals
The client with a focus on developing pipeline asset for KRAS G12C segment sought granular insights for competitive edge in treatment sequencing.